Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01853592 · ClinicalTrials.gov registry record
Gadofosveset Trisodium for Heart Imaging Studies
A clinical trial, sponsored by National Institutes of Health Clinical Center (CC).
- Completed
- Registry status
- 30
- Enrollment target
NCT01853592: Completed study, sponsored by National Institutes of Health Clinical Center (CC).
NCT01853592 is a clinical trial that has completed, run by National Institutes of Health Clinical Center (CC). The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01853592 has completed, sponsored by National Institutes of Health Clinical Center (CC).
- COMPLETED
- Registry status
- 30 participants
- Enrollment target
Study Summary
Background: \- Magnetic resonance imaging (MRI) is type of imaging study that uses magnetic fields and radio waves to take pictures of the body. To help the images show up more clearly, a contrast agent is injected into a vein. Researchers are interested in finding contrast agents that can help show problems with the blood vessels around the heart. They want to test an agent called Gadofosveset Trisodium to see how it works in MRI scans. Objectives: \- To test the effectiveness of Gadofosveset Trisodium as a contrast agent in heart MRI scans. Eligibility: \- Healthy volunteers between 18 and 45 years of age. Design: * Participants will be screened with a physical exam and medical history. They will provide blood samples before the scanning sessions. * Participants will have an MRI scan after the screening visit. They will have a dose of the contrast scan before the study. * Participants will return for one additional MRI scan within 1 to 2 months of each scan. Different doses of the contrast agent will be used for each scan. * An additional blood sample will be collected within 1 week of the second MRI scan.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2013-03-08 |
| Est. Completion | 2016-12-13 |
What the finished NCT01853592 record still lists
NCT01853592 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 30 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT01853592 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01853592 about?
NCT01853592 is a clinical study titled "Gadofosveset Trisodium for Heart Imaging Studies". Background: \- Magnetic resonance imaging (MRI) is type of imaging study that uses magnetic fields and radio waves to take pictures of the body. To help the images show up more clearly, a contrast agent is injected into a vein. Researchers are interested in finding contrast agents that can help sho...
What is the current status of trial NCT01853592?
This trial is currently completed. The enrollment target is 30 participants. The study started on 2013-03-08. Estimated completion is 2016-12-13.
Who is sponsoring clinical trial NCT01853592?
This trial is sponsored by National Institutes of Health Clinical Center (CC), which has 338 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI